HighTide Therapeutics’ Post

Greetings from San Diego, where the American Association for the Study of Liver Diseases (AASLD) 𝗟𝗶𝘃𝗲𝗿 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 is in full swing! Thanks to all who stopped by our posters yesterday to learn about post-hoc analyses of a Phase 2a study into our oral berberine ursodeoxycholate (HTD1801) in patients with MASH and co-morbid type 2 diabetes. Stay tuned for Centricity (MASH Ph2b) topline results in the first half of 2025! #MASH #diabetes #liverdisease #metabolicdisease #obesity #gastrointestinal #GI #drugdevelopment #TLM24 #LiverMeeting

  • No alternative text description for this image
  • No alternative text description for this image

To view or add a comment, sign in

Explore topics